First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
The laboratory is equipped to perform high-volume diagnostic testing services
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
He has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited.
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
Subscribe To Our Newsletter & Stay Updated
